Clinical Trial Detail

NCT ID NCT03592641
Title Volitinib in Treating Participants With MET Amplified Metastatic or Unresectable Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Savolitinib

Age Groups: senior adult

Additional content available in CKB BOOST